Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction

Anthony V. Moorman; Amir Enshaei; Daniel Murdy; Melvin Joy; Judith M. Boer; Monique L. den Boer; Rob Pieters; Valerie de Haas; Martin A. Horstmann; Gabriele Escherich; Bertil Johansson; Hanne V. Marquart; Kjeld Schmiegelow; Jeremy Hancock; John Moppett; Mats Heyman

doi:10.1038/s41375-024-02329-0

Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction

Anthony V. Moorman^*, Amir Enshaei, Daniel Murdy, Melvin Joy, Judith M. Boer, Monique L. den Boer, Rob Pieters, Valerie de Haas, Martin A. Horstmann, Gabriele Escherich, Bertil Johansson, Hanne V. Marquart, Kjeld Schmiegelow, Jeremy Hancock, John Moppett, Mats Heyman

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Letter › peer review

1 Citationer (Scopus)

12 Downloads (Pure)

Originalsprog	Engelsk
Tidsskrift	Leukemia
Vol/bind	38
Udgave nummer	9
Sider (fra-til)	2023-2026
Antal sider	4
ISSN	0887-6924
DOI	https://doi.org/10.1038/s41375-024-02329-0
Status	Udgivet - 2024

Bibliografisk note

Funding Information:
The authors thank all the patients who took part in these trial as well as their families. This study was supported by research grants from Cancer Research UK (CRCBPA-Jul21\\100004) and Blood Cancer UK (#15036). Vincent H.J. van der Velden (Erasmus MC), Christa H.E. Homburg (Sanquin, Amsterdam) and H. Berna Beverloo (Erasmus MC) are acknowledged for their contribution to the MRD and cytogenetic analysis of the DCOG ALL10 patients. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.

Adgang til dokumentet

10.1038/s41375-024-02329-0Licens: CC BY

FulltextForlagets udgivne version, 829 KBLicens: CC BY

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

Moorman, A. V., Enshaei, A., Murdy, D., Joy, M., Boer, J. M., den Boer, M. L., Pieters, R., de Haas, V., Horstmann, M. A., Escherich, G., Johansson, B., Marquart, H. V., Schmiegelow, K., Hancock, J., Moppett, J., & Heyman, M. (2024). Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction. Leukemia, 38(9), 2023-2026. https://doi.org/10.1038/s41375-024-02329-0

Moorman, AV, Enshaei, A, Murdy, D, Joy, M, Boer, JM, den Boer, ML, Pieters, R, de Haas, V, Horstmann, MA, Escherich, G, Johansson, B, Marquart, HV , Schmiegelow, K, Hancock, J, Moppett, J & Heyman, M 2024, 'Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction', Leukemia, bind 38, nr. 9, s. 2023-2026. https://doi.org/10.1038/s41375-024-02329-0

@article{5543e51d71e148d3b1e4ca771375560b,

title = "Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction",

author = "Moorman, {Anthony V.} and Amir Enshaei and Daniel Murdy and Melvin Joy and Boer, {Judith M.} and {den Boer}, {Monique L.} and Rob Pieters and {de Haas}, Valerie and Horstmann, {Martin A.} and Gabriele Escherich and Bertil Johansson and Marquart, {Hanne V.} and Kjeld Schmiegelow and Jeremy Hancock and John Moppett and Mats Heyman",

note = "Funding Information: The authors thank all the patients who took part in these trial as well as their families. This study was supported by research grants from Cancer Research UK (CRCBPA-Jul21\\100004) and Blood Cancer UK (#15036). Vincent H.J. van der Velden (Erasmus MC), Christa H.E. Homburg (Sanquin, Amsterdam) and H. Berna Beverloo (Erasmus MC) are acknowledged for their contribution to the MRD and cytogenetic analysis of the DCOG ALL10 patients. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission. ",

year = "2024",

doi = "10.1038/s41375-024-02329-0",

language = "English",

volume = "38",

pages = "2023--2026",

journal = "Leukemia",

issn = "0887-6924",

publisher = "nature publishing group",

number = "9",

}

TY - JOUR

T1 - Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction

AU - Moorman, Anthony V.

AU - Enshaei, Amir

AU - Murdy, Daniel

AU - Joy, Melvin

AU - Boer, Judith M.

AU - den Boer, Monique L.

AU - Pieters, Rob

AU - de Haas, Valerie

AU - Horstmann, Martin A.

AU - Escherich, Gabriele

AU - Johansson, Bertil

AU - Marquart, Hanne V.

AU - Schmiegelow, Kjeld

AU - Hancock, Jeremy

AU - Moppett, John

AU - Heyman, Mats

N1 - Funding Information: The authors thank all the patients who took part in these trial as well as their families. This study was supported by research grants from Cancer Research UK (CRCBPA-Jul21\\100004) and Blood Cancer UK (#15036). Vincent H.J. van der Velden (Erasmus MC), Christa H.E. Homburg (Sanquin, Amsterdam) and H. Berna Beverloo (Erasmus MC) are acknowledged for their contribution to the MRD and cytogenetic analysis of the DCOG ALL10 patients. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.

PY - 2024

Y1 - 2024

U2 - 10.1038/s41375-024-02329-0

DO - 10.1038/s41375-024-02329-0

M3 - Letter

C2 - 38965371

AN - SCOPUS:85197502631

SN - 0887-6924

VL - 38

SP - 2023

EP - 2026

JO - Leukemia

JF - Leukemia

IS - 9

ER -